NOSE AND PARANASAL SINUSES: Edited by Samuel S. Becker and Nithin D. AdappaWhat is the evidence for genetics in chronic rhinosinusitis?Yoo, Frederick; Suh, Jeffrey D. Author Information Department of Head and Neck Surgery, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA Correspondence to Jeffrey D. Suh, MD, Assistant Professor, Department of Head and Neck Surgery, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave 62-132 CHS, Los Angeles, CA 90095-1624, USA. Tel: +1 310 206 6766; fax: +1 310 206 1393; e-mail: [email protected] Current Opinion in Otolaryngology & Head and Neck Surgery: February 2017 - Volume 25 - Issue 1 - p 54-63 doi: 10.1097/MOO.0000000000000329 Buy Metrics Abstract Purpose of review To perform analysis of evidence in current literature on the topic of genetics and chronic rhinosinusitis (CRS), with a particular focus on recent findings in the cystic fibrosis transmembrane regulator (CFTR), genes associated with primary ciliary dyskinesia, and taste receptor T2R38. Other genes that have been found to have association with CRS are also presented and discussed. Recent findings Recent studies in CFTR and CRS research have investigated possible CFTR-potentiators for treatment of refractory CRS. The T2R38 gene has been shown to be applicable in the clinical setting with a testable phenotype and may have a role in the prognosis and influencing management strategies of CRS patients. Many genes of the immune system have been studied, with genome-wide association studies and candidate-gene approaches identifying new associations that will need replication and further elucidation. Summary CRS is a multifactorial disease, with strong evidence of a genetic component in its pathophysiology for some cases. Currently, there are over 70 genes that have been genetically associated with CRS in the past 15 years. Future investigations into genetic causes and predispositions of CRS may allow for improved prognostication and development of disease-prevention strategies as well as novel therapeutic targets. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.